The pathway study: Results of a pilot feasibility study in patients suspected of having lung carcinoma investigated in a conventional chest clinic setting compared to a centralised two-stop pathway

Lung Cancer

Volumn 42, Issue 3, 2003, Pages 283-290

  Murray, P V ^a   O'Brien, M E R ^a   Sayer, R ^b   Cooke, N ^c   Knowles, G ^d   Miller, A C ^e   Varney, V ^c   Rowell, N P ^a   Padhani, A R ^a   MacVicar, D ^a   Norton, A ^a   Ashley, S ^a   Smith, I E ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b ST GEORGE S HOSPITAL   (United Kingdom)

^c ST HELIER HOSPITAL   (United Kingdom)

^d KINGSTON HOSPITAL   (United Kingdom)

^e MAYDAY UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Delay; Diagnosis; Fast track pathway; Lung cancer

Indexed keywords

ANTINEOPLASTIC AGENT;

AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; FATIGUE; FEASIBILITY STUDY; FEMALE; GENERAL PRACTITIONER; HUMAN; INTERMETHOD COMPARISON; LUNG CARCINOMA; MALE; NAUSEA; OUTPATIENT DEPARTMENT; PATIENT SATISFACTION; PHYSICIAN; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

EID: 10744224820     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(03)00358-1     Document Type: Article

References (28)

1. Pearson F.G. Current status of surgical resection of lung cancer. Chest. 106:1984;337-395.
2. Sause W.T. Nonsurgical management of non-small-cell lung cancer. Hematol. Oncol. Clin. North Am. 15(2):2001;277-289.
3. Kesson E., Bucknall C.E., McAlpine L.G., Milroy R., Hole D., Vernon D.R.H.et al. Lung cancer - management and outcome in Glasgow, 1991-92. Br. J. Cancer. 78(10):1998;1391-1395.
4. Watkin S.W., Hayhurst G.K., Green J.A. Time trends in the outcome of lung cancer management: a study of 9,090 cases diagnosed in the Mersey Region 1974-86. Br. J. Cancer. 61:1990;590-596.
5. Gregor A., Thomson C.S., Brewster D.H.et al. Management and survival of patients with lung cancer in Scotland diagnosed in 1995: results of a national population based study. Thorax. 56:2001;212-217.
6. Humphrey E.W., Smart C.R., Winchester D.P.et al. National survey of the pattern of care for carcinoma of the lung. J. Thorac. Cardiovasc. Surg. 100:1990;837-843.
7. Geddes D.M. The natural history of lung cancer: a review based on rates of tumour growth. Br. J. Dis. Chest. 73(1):1979;1-17.
8. Spiro S.G. Lung Tumours. In: R.A.L. Brewis, G.J. Gibson, D.M. Geddes (Eds.), Respiratory medicine. London: Balliere Tindall; 1990. p. 832-79.
9. Billing J.S., Wells F.C. Delays in the diagnosis and surgical treatment of lung cancer. Thorax. 51(9):1996;903-906.
10. Melamed M.R., Flehinger B.J., Zaman M.B.et al. Screening for early lung cancer. Results of the Memorial Sloan-Kettering study in New York. Chest. 86(1):1984;44-53.
11. Frost J.K., Ball W.C. Jr., Levin M.L.et al. Early lung cancer detection: results of the initial (prevalence) radiologic and cytologic screening in the Johns Hopkins study. Am. Rev. Respir. Dis. 130(4):1984;549-554.
12. Fontana R.S., Sanderson D.R., Woolner L.B., Taylor W.F., Miller W.E., Muhm J.R. Lung cancer screening: the Mayo program. J. Occup. Med. 28(8):1986;746-750.
13. Patz E.F. Jr., Rossi S., Harpole D.H.et al. Correlation of tumor size and survival in patients with stage IA non-small cell lung cancer. Chest. 117(6):2000;1568-1571.
14. Henschke C.I., McCauley D.I., Yankelevitz D.F.et al. Early Lung Cancer Action Project: overall design and findings from baseline screening. Lancet. 354(9173):1999;99-105.
15. Itoh S., Satake H., Katoh T.et al. Helical CT for lung-cancer screening: fourth report. Detectability of pulmonary lesions. Nippon Igaku Hoshasen Gakkai Zasshi. 56(14):1996;1039-1044.
16. Clinical Oncology Information Network (COIN). Guidelines on the non-surgical management of lung cancer. Clin Oncol 1999;11:S1-56.
17. Cancer Guidance Subgroup of the Clinical Outcome Group (COG). Guidance for purchasers: improving outcomes in lung cancer; June 1998.
18. The Lung Cancer Working Party of the British Thoracic Society Standards of Care Committee. BTS recommendations to respiratory physicians for organising the care of patients with lung cancer. Thorax 1998;53:S1-8.
19. Whitehouse JMA. Management of lung cancer: current clinical practices. Standing Medical Advisory Committee; 1994.
20. The NHS Cancer Plan, 2000. http://www.doh.gov.uk/cancer .
21. Laroche C., Wells F., Coulden R.et al. Improving surgical resection rate in lung cancer. Thorax. 53:1998;445-449.
22. Fergusson R.J., Gregor A., Dodds R., Kerr G. Management of lung cancer in South East Scotland. Thorax. 51:1996;569-574.
23. Bozcuk H., Martin C. Does treatment delay affect survival in non-small cell lung cancer? A retrospective analysis from a single UK centre. Lung Cancer. 34:2001;243-252.
24. Aragoneses F.G., Moreno N., Leon P., Fontan E.G., Folque E. Influence of delays on survival in the surgical treatment of bronchogenic carcinoma. Lung Cancer. 36:2002;59-63.
25. Aaronson N.K., Ahmedzai S., Bergman B.et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J. Natl. Cancer Inst. 85(5):1993;365-376.
26. Moore S., Corner J., Fuller F. Development of nurse-led follow-up in the management of patients with lung cancer. NT Res. 4(6):1997;432-445.
27. Anderson H., Hopwood P., Stephens R.J.et al. Gemcitabine plus best supportive care (BSC) vs. BSC in inoperable non-small cell lung cancer - a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer. Br. J. Cancer. 83(4):2000;447-453.
28. Cullen M.H., Billingham L.J., Woodroffe C.M.et al. Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. J. Clin. Oncol. 17(10):1999;3188-3194.